{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457288866
| IUPAC_name = 4,5,6,7-tetrahydroisoxazolo[5,4-''c'']pyridin-3(2''H'')-one
| image = Gaboxadol.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 4322
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 64603-91-4
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 3448
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3330
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = K1M5RVL18S
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04282
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 312443

<!--Chemical data-->
| C=6 | H=8 | N=2 | O=2 
| molecular_weight = 140.14 g/mol
| smiles = O=C1/C2=C(\ON1)CNCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZXRVKCBLGJOCEE-UHFFFAOYSA-N
}}

'''Gaboxadol''', also known as 4,5,6,7-'''t'''etra'''h'''ydro'''i'''soxazolo(5,4-c)'''p'''yridin-3-ol ('''THIP'''), is a conformationally constrained derivative of the [[alkaloid]] [[muscimol]] that was first synthesized in 1977 by the Danish [[chemist]] Povl Krogsgaard-Larsen.<ref name=Hamilton>{{cite web|url=http://harpers.org/archive/2013/08/gaboxadol/ |title=Gaboxadol |last=Morris, Hamilton |publisher=Harper's Magazine |date=August 2013 |accessdate=2014-11-20}}</ref> In the early 1980s gaboxadol was the subject of a series of [[pilot studies]] that tested its efficacy as an analgesic and anxiolytic, as well as a treatment for [[tardive dyskinesia]], [[Huntington's disease]], [[Alzheimer's disease]], and [[spasticity]].<ref name="Hamilton"/> It was not until 1996 that researchers attempted to harness gaboxadol's frequently reported sedative "[[adverse effect]]" for the treatment of insomnia, resulting in a series of clinical trials sponsored by [[Lundbeck]] and [[Merck & Co.|Merck]].<ref name="Hamilton"/><ref>US Patent 4278676 - Heterocyclic compounds</ref> In March, 2007, Merck and Lundbeck cancelled work on the drug, citing safety concerns and the failure of an efficacy trial. It acts on the [[Gamma-aminobutyric acid|GABA]] system, but in a different way from [[benzodiazepine]]s, [[nonbenzodiazepine|Z-Drugs]], and [[barbiturate]]s. Lundbeck states that gaboxadol also increases [[Non-rapid eye movement sleep|deep sleep]] (stage 4). It is, however, not reinforcing like [[benzodiazepines]] are.<ref>{{Cite journal
 | pmid = 22496576
| year = 2012
| author1 = Vashchinkina
| first1 = E
| title = GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons
| journal = Journal of Neuroscience
| volume = 32
| issue = 15
| pages = 5310-20
| last2 = Panhelainen
| first2 = A
| last3 = Vekovischeva
| first3 = O. Y.
| last4 = Aitta-Aho
| first4 = T
| last5 = Ebert
| first5 = B
| last6 = Ator
| first6 = N. A.
| last7 = Korpi
| first7 = E. R.
| doi = 10.1523/JNEUROSCI.4697-11.2012
}}</ref>

In 2015, Lundbeck sold its rights to the molecule to Ovid Therapeutics, whose plan is to develop it for [[fragile X syndrome|FXS]] and [[Angelman Syndrome]].<ref name=CNBC>{{cite web|url=https://www.cnbc.com/id/102591288 |title=Former Teva CEO's new gig at Ovid Therapeutics |last=Tirrell, Meg |publisher=CNBC |date=16 April 2015 |accessdate=2015-05-06}}</ref> It is known internally in Ovid as '''OV101'''

==See also==
* ''[[Amanita muscaria]]''
* [[CI-966]]

==References==
{{Reflist|2}}

==External links==
* {{MeshName|4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol}}
* [http://www.lundbeck.com/ H. Lundbeck Website]
* [http://www.medicalnewstoday.com/medicalnews.php?newsid=55678 Medical News Today article]
* [https://www.nytimes.com/2007/03/29/business/29sleep.html?ref=health Report of cancellation of development].
* [http://harpers.org/archive/2013/08/gaboxadol/ Gaboxadol]

{{Hypnotics and sedatives}}
{{GABAergics}}
{{Glycinergics}}

[[Category:GABAA receptor agonists]]
[[Category:GABAA-rho receptor antagonists]]
[[Category:Glycine receptor antagonists]]
[[Category:Sedatives]]
[[Category:Isoxazolidinones]]
[[Category:Anticonvulsants]]
[[Category:Danish inventions]]
{{sedative-stub}}